Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
A Study of LY3484356 in Healthy Female Participants
- Conditions
- Interventions
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 82
- Registration Number
- NCT04840888
- Locations
- 🇺🇸
LabCorp CRU, Inc., Daytona Beach, Florida, United States
🇺🇸Covance Dallas, Dallas, Texas, United States
Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 131
- Registration Number
- NCT04718181
- Locations
- 🇺🇸
Dallas Clinical Research Unit, Dallas, Texas, United States
🇺🇸Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States
🇺🇸Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States
Drug-drug Interaction Study of KL1333 in Healthy Subjects
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Abliva AB
- Target Recruit Count
- 14
- Registration Number
- NCT04643249
- Locations
- 🇬🇧
Volunteer recruitment center Covance Leeds Covance Leeds, Leeds, United Kingdom
Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- University of Southern Denmark
- Target Recruit Count
- 10
- Registration Number
- NCT04504045
- Locations
- 🇩🇰
University of Southern Denmark, Odense, Region Of Southern Denmark, Denmark
Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2020-09-04
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT04368585
- Locations
- 🇺🇸
Medical Facility, Phoenix, Arizona, United States
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT04246762
- Locations
- 🇧🇬
Comac Medical Ltd, Sofia, Bulgaria
🇲🇩ICS ARENSIA Exploratory Medicine SRL, a daughter company of ARENSIA Exploratory Medicine GmbH,Republican Clinical Hospital, Chisinau, Moldova, Republic of
Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers
- Conditions
- Interventions
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- University of Sarajevo
- Target Recruit Count
- 15
- Registration Number
- NCT04198948
- Locations
- 🇧🇦
General Hospital Prim. Dr. Abdulah Nakas, Sarajevo, Bosnia and Herzegovina
Oral Omeprazole in Bleeding Peptic Ulcer
- First Posted Date
- 2019-11-20
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 100
- Registration Number
- NCT04170270
A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881
- Conditions
- Interventions
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Agios Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04128787
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04108676
- Locations
- 🇨🇳
The third xiangya hospital Hospital,of central south university, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.